Clinical companies

Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.

Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions including: non-small cell lung cancer, melanoma, adrenomyeloneuropathy, Gaucher disease and liver transplantation using a variety of modalities, including small molecules, cell therapy and gene therapy.